Trial Profile
Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer: a Phase ll Randomised Trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 15 Apr 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Oleclumab (Primary) ; Cyclophosphamide; Doxorubicin; Paclitaxel
- Indications Adenocarcinoma; Early breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms Neo-CheckRay
- 13 Mar 2024 Planned End Date changed from 15 Jan 2026 to 30 Sep 2029.
- 13 Mar 2024 Planned primary completion date changed from 31 Jan 2024 to 30 Sep 2024.
- 13 Mar 2024 Status changed from recruiting to active, no longer recruiting.